Business

India’s Pharma Market Grows 8.4% In FY25; Boosted By Chronic Therapies & New Drug Launches

India’s pharma market grew by 8.4% during the financial year 2024-25, propelled by strong performance in key chronic therapy areas, according to market research firm Pharmarack.

The cardiac segment led with a 10.8% value growth, followed closely by gastrointestinal (10.2%) and anti-diabetic (8%) therapies.

Together, these three therapy areas contributed 34% of the total pharma market sales, helping push the industry’s overall turnover to over ₹2.25 trillion.

Top-Selling Drugs Led By Chronic Treatments

Despite the chronic therapies dominating in growth, GSK’s antibiotic Augmentin emerged as the top-selling drug of FY25 with ₹816 crore in sales.

USV’s Glycomet GP, an anti-diabetic medication, followed closely with ₹803 crore in sales.

While value growth was strong, unit sales in the domestic market recorded a modest 1.2% increase, indicating that growth was largely price-driven.

Empagliflozin Patent Expiry Sparks Price War

March 2025 saw a significant market shift with the diabetes molecule empagliflozin going off-patent.

Within a month, 86 brands from 19 companies launched empagliflozin-based products. Sheetal Sapale, vice-president (commercial) at Pharmarack, noted a steep price drop—around 85%—with prices falling from ₹60-70 per tablet to just ₹5-15.

Despite a rise in volume, the value declined due to this price erosion.

Anti-Obesity Market Gets Boost From Mounjaro

The launch of Eli Lilly’s Mounjaro (tirzepatide) in March 2025 added momentum to India’s emerging anti-obesity market.

In just one month, Mounjaro contributed ₹1.4 crore to the segment’s ₹576 crore moving annual turnover. Semaglutide, another GLP-1-based drug, accounted for 69% of this total over the previous 12 months.

Double-Digit Growth For Leading Companies

Several leading pharma companies posted strong domestic value growth in March 2025. Sun Pharma (14.9%), Torrent Pharma (14.7%), Intas (12.8%), and Zydus (10.8%) all recorded double-digit growth.

Overall, the pharma market witnessed a 7.5% value growth and 1.8% unit growth in March alone, reflecting broad-based strength across segments.

Also Read: India’s $2.7 Billion PLI Scheme Set To Boost Local Electronics Manufacturing

Purnima Mishra

Recent Posts

UN Chief Urges Immediate Ceasefire In Gaza; Highlights Deepening Humanitarian Crisis

UN Secretary-General Antonio Guterres has called for an immediate ceasefire in Gaza, following the temporary…

19 mins ago

Horoscope Today, 28 June 2025: Know What Your Zodiac Sign Says!

Horoscope Today, 28 June 2025: Curious what the stars have in store? Discover how your…

2 hours ago

4415 Indians Evacuated From Iran And Israel Under ‘Operation Sindhu’: MEA

India evacuated 4,415 nationals from Iran and Israel under Operation Sindhu, the MEA said Friday,…

9 hours ago

PM Modi To Embark On Five-Nation Tour To Strengthen Global Partnerships

PM Narendra Modi will embark on a five-nation tour from July 2, visiting Ghana, Trinidad…

10 hours ago

Allahabad HC Directs UPPSC To Allow Petitioner A Scribe For PCS Main Exam

The Allahabad HC has directed the UPPSC to allow petitioner Sameer Khan to use a…

10 hours ago

Allahabad High Court Slams UP Officials For Defying Judicial Orders

The Allahabad High Court strongly rebuked three senior officials from Baghpat district, the Collector, SDM…

10 hours ago